DOBUTAMINE INJECTION USP 12.5 MG — DIN 02242010
DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) : 12.5 MG · SANDOZ CANADA INCORPORATED · LIQUID · wholesale supply in Canada
Health Canada status: MARKETED
What is DOBUTAMINE INJECTION USP?
DOBUTAMINE INJECTION USP 12.5 MG contains DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) : 12.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02242010, held by SANDOZ CANADA INCORPORATED, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 06-Oct-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOBUTAMINE INJECTION USP used for?
Dobutamine Injection USP is indicated in the treatment of adults with cardiac decompensation due to depressed contractility resulting from organic heart disease or following cardiac surgical procedures in which parenteral therapy is necessary for inotropic support.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Dobutamine cost around the world?
Dobutamine is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 5 | 6 | SAR███.██ |
| South Africa | single exit price | 5 | 6 | ZAR███.██ |
| Morocco | PPV (public price) | 4 | 4 | MAD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
21 pack listings across 19 brand entries and 5 price bases, refreshed 05 Sep 2026. Ranges span every Dobutamine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Dobutamine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Dobutamine, across 9 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 2 | 1 | DOBUTAMINE INJECTION SDZ, DOBUTAMINE INJECTION USP | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | DOBUTAMINE INJECTION USP | Sourceable in Canada |
| IVAX PHARMACEUTICALS INCORPORATED | 1 | 0 | DOBUTAMINE 12.5MG/ML | No marketed DIN |
| NOVOPHARM LIMITED | 1 | 0 | DOBUTAMINE HYDROCHLORIDE INJECTION-12.5MG/ML | No marketed DIN |
| PFIZER CANADA ULC | 1 | 0 | DOBUTAMINE INJECTION USP | No marketed DIN |
| PHARMACEUTICAL PARTNERS OF CANADA INC | 1 | 0 | DOBUTREX | No marketed DIN |
| SANOFI CANADA, INC. | 1 | 0 | DOBUTAMINE HYDROCHLORIDE INJECTION-12.5MG/ML | No marketed DIN |
| STERIMAX INC | 1 | 0 | DOBUTAMINE INJECTION USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 12.5 MG |
|---|---|
| Dosage form | LIQUID |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Dobutamine Injection USP is available in 20 mL single use vials, boxes of 10. |
| Storage | Store between 15 and 30 °C. Protect from light. Discard unused portion. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Dobutamine |
|---|---|
| ATC code | C01CA07 |
| AHFS class | 12:12.08.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02242010 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2242010 |
| Brand name | DOBUTAMINE INJECTION USP |
| Generic / active ingredient | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) : 12.5 MG |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
| Health Canada schedule | Prescription |
| ATC code | C01CA07 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01CA |
| Current status | MARKETED |
| Status date | 06-Oct-2005 |
| Original market date | 2000-10-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Note: DOBUTAMINE INJECTION USP is a potent drug; it is not for direct injection and must be diluted exactly as directed before administration to patients as an intravenous infusion (see PRECAUTIONS). Preparation and Stability: Dobutamine Injection USP is incompatible with alkaline solutions and should not be mixed with products such as 5% sodium bicarbonate injection. Because of the occurrences of physical incompatibilities with some drugs and the potential for incompatibility with other drugs, it is recommended that Dobutamine Injection USP not be mixed with other drugs in the same solution. Dobutamine Injection USP should not be used in conjunction with other agents or diluents containing both sodium bisulfite and ethanol. The diluted solution should be inspected visually for discolouration, haziness, particulate matter and leakage prior to administration. Discard any unused portion. Dobutamine Injection USP must be diluted at the time of administration to at least 50 mL with either Dextrose 5% or Sodium Chloride 0.9% prior to administration by IV infusion. Intravenous solutions should be used within 24 hours of preparation. Solutions containing dobutamine may exhibit a colour that, if present, will increase with time. This colour change is due to slight oxidation of the drug, but there is no significant loss of potency during the reconstituted time periods stated above. Recommended Dosage: The rate of infusion needed to increase cardiac output usually ranges from 2.5 to 10 µg/kg/min (see Table). Some patients may respond to doses as low as 0.5 µg/kg/min.; whereas, on rare occasions, infusion rates up to 40 µg/kg/min. have been required to obtain the desired effect. The final volume administered should be determined by the fluid requirements of the patient. The rate of administration and duration of therapy should be adjusted according to the patient's response as determined by heart rate, presence of ectopic activity, blood pressure, urine flow and, whenever possible, measurement of central venous or pulmonary wedge pressure and cardiac output.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Dobutamine Injection USP is contraindicated in patients with pheochromocytoma, idiopathic hypertrophic subaortic stenosis, and in those patients with hypersensitivity to dobutamine.
Warnings and precautions
Dobutamine Injection USP may cause a marked increase in heart rate or blood pressure, especially systolic pressure. About 10% of patients in clinical studies have had rate increases of 30 beats per minute or more, while about 7.5% have had a 50 mm Hg or greater increase in systolic pressure. Patients with pre-existing hypertension appear to have an increased risk of developing an exaggerated pressor response. A reduction of the dosage usually reverses these effects promptly. Dobutamine may precipitate or exacerbate ventricular ectopic activity but has rarely caused ventricular tachycardia. Reactions suggestive of hypersensitivity associated with administration of Dobutamine Injection USP, including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally. Dobutamine Injection USP contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms, in certain susceptible people. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to instituting therapy with Dobutamine Injection USP. Because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response. Dobutamine Injection USP should not be used in the presence of uncorrected tachycardia or ventricular fibrillation. No improvement may be observed in the presence of marked mechanical obstruction such as severe valvular aortic stenosis. Minimal vasoconstriction has occasionally been observed, most notably in patients recently treated with a ẞ-blocking drug. Because the inotropic effect of Dobutamine Injection USP stems from stimulation of cardiac ẞ₁ receptors, this effect is, of course, prevented by ẞ-blocking drugs.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOBUTAMINE INJECTION USP | 12.5 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02462729 |
| DOBUTAMINE 12.5MG/ML | 12.5 MG | SOLUTION | IVAX PHARMACEUTICALS INCORPORATED | CANCELLED POST MARKET | 02229451 |
| DOBUTAMINE HYDROCHLORIDE INJECTION-12.5MG/ML | 12.5 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | 02225891 |
| DOBUTAMINE HYDROCHLORIDE INJECTION-12.5MG/ML | 12.5 MG | LIQUID | NOVOPHARM LIMITED | CANCELLED POST MARKET | 02228335 |
| DOBUTAMINE INJECTION SDZ | 12.5 MG | SOLUTION | SANDOZ CANADA INCORPORATED | DORMANT | 02384671 |
| DOBUTAMINE INJECTION USP | 12.5 MG | SOLUTION | STERIMAX INC | APPROVED | 02443430 |
| DOBUTAMINE INJECTION USP | 250 MG / 20 ML | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02210401 |
| DOBUTREX | 12.5 MG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | 00759538 |
2 · Same class — other molecules in ATC C01CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Midodrine | AMATINE · APO-MIDODRINE · JAMP MIDODRINE · M-MIDODRINE · +2 more | 12 | 10 | Yes |
| Epinephrine | ADRENACLICK 0.15MG AUTO-INJECTOR · ADRENACLICK 0.30MG AUTO-INJECTOR · ADRENALIN · ALLERJECT · +17 more | 29 | 7 | Yes |
| Phenylephrine | NEO-SYNEPHRINE · NEO-SYNEPHRINE INJ LIQ 10MG/ML · NEO-SYNEPHRINE LIQ 1% · PHENYLEPHRINE HYDROCHLORIDE INJECTION · +4 more | 15 | 5 | Yes |
| Norepinephrine | LEVOPHED · LEVOPHED LIQ IV 1.0MG/ML · NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE INJECTION · NOREPINEPHRINE BITARTRATE INJECTION · +2 more | 10 | 5 | Yes |
| Dopamine | DOPAMINE HCL 0.8MG/ML DEXTROSE 5% INJ USP · DOPAMINE HCL 1.6MG/ML DEXTROSE 5% INJ USP · DOPAMINE HCL 3.2MG/ML DEXTROSE 5% INJ USP · DOPAMINE HCL INJ 4% · +2 more | 8 | 3 | Yes |
| Isoprenaline | ISOPROTERENOL HCL INJ 1:5000 · ISOPROTERENOL HYDROCHLORIDE INJECTION USP · ISUPREL INJ 0.2MG/ML · ISUPREL LIQ 0.2MG/ML | 7 | 3 | Yes |
| Dobutamine | DOBUTAMINE 12.5MG/ML · DOBUTAMINE HYDROCHLORIDE INJECTION-12.5MG/ML · DOBUTAMINE INJECTION SDZ · DOBUTAMINE INJECTION USP · +1 more | 9 | 2 | Yes |
| Ephedrine | EPHEDRINE SULFATE INJECTION USP · EPHEDRINE SULFATE INJECTION USP, 50MG/ML · EPHEDRINE SULFATE INJECTION, USP · EPHEDRINE SULPHATE INJECTION, USP | 6 | 1 | Yes |
| Epinephrine, Combinations | ANA-KIT · ANA-KIT (2MG/TAB ORL, 1MG/ML LIQ SC IM) · ANAKIT INSECT STING TREATMENT KIT | 3 | 0 | Not in Canada |
| Mephentermine | WYAMINE SULFATE INJECTION LIQ 30MG/ML | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C01CE | Amrinone · Milrinone | 12 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DOBUTAMINE INJECTION USP called?
Also recorded in Canada as: Dobutamine (GLOBAL), Dobutrex (US), Dobutrex (UK), Dobutrex (IN), Dobutamine Hydrochloride (US), Dobutamine Hydrochloride (UK), Dobutamine Hydrochloride (JP), Inotrex (IN), Cardiject (IN), Dobucin (EU), Dobutamin-Hameln (EU), Dobutamin Fresenius Kabi (EU).
The same molecule, Dobutamine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CARDIJECT | Latin | Morocco |
| Cardutrex | Latin | Saudi Arabia |
| DOBUTAMINE MYLAN | Latin | Morocco |
| Dobutrex | Latin | South Africa |
| Micro-Dobutamine | Latin | South Africa |
| Posiject | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.